Immunai is a biotech company that combines single cell genomics with ML algorithms to enable high resolution profiling of the immune system.
Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses.
Immunai was founded in December 2018 by Noam Solomon, Luis Voloch, Danny Wells, Ansuman Satpathy and Dan Littman. The company is headquartered in New York, New York.
Immunai uses largely proprietary technology to leverage single-cell analysis and machine learning to uncover patterns within the immune system that are biologically relevant among diseases and treatment modalities.
Immunai is comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.
Immunai has raised $20M in a Seed round of funding on May 14, 2020. Investors included Viola Ventures and TLV Partners.